http://prtimes.jp/main/html/rd/p/000000016.000088821.html

Following the Series A round conducted last year, we have carried out fundraising through a third-party allotment of new shares, with Rohto Pharmaceutical Co., Ltd. as the primary underwriter.

Based on the funds raised this time, we will further accelerate clinical research and clinical trials for products currently under development, aiming for early social implementation (market launch). In addition, together with Rohto Pharmaceutical Co., Ltd., which invested in this round, our partner companies that invested last year, and the companies collaborating with us on various projects, we will build an exit strategy for smooth market introduction and work to provide solutions to more patients and healthcare professionals more quickly.